The Effect of Antihypertensive Drugs on the Serum Level of Angiotensin-Converting Enzyme 2 (ACE2) in Hypertensive Patients with Severe COVID-19 Infection
Abstract
Although many studies were conducted worldwide on the effect of angiotensin converting enzyme inhibition on the morbidity and mortality of the patients with COVID-19, these studies have varied in their conclusions due to differences in populations, races, and ethnicity. This work aimed to study the effect of different antihypertensive drugs on the serum level of angiotensin-converting enzyme-2 in severely infected COVID-19 patients with hypertension. This study was conducted in Al-Nahrain University/College of Medicine/Chemistry and Biochemistry Department and Al-Mustansyria University /College of Medicine / Department of Medicine, Baghdad, Iraq. The study included 50 patients with confirmed severe COVID-19 infection: 25 COVID-19 patients with hypertension administered to the hospital, and 25 COVID-19 patients without hypertension administered to the hospital during the period from January, 2022 to September, 2022. The hypertensive patients were on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Calcium-channel blockers or beta blockers prior to COVID-19 infection. The median level of angiotensin converting enzyme-2 (ACE2) in hypertensive patients was 3.22ng/ml (range 1.34-6.89 ng/ml) compared with0.89 ng/ml (range 0.22-1.35 ng/ml) in non-hypertensive group, with a highly significant difference. The study also showed a significantly higher level of serum ACE2 in patients on ACE inhibitors (median= 4.85 ng/ml, range= 3.22-6.89 ng/ml) than either of hypertensive patients taking ARBs (median= 2.56 ng/ml, range= 2.27-4.34 ng/ml) or those on Ca-channel blockers (median= 2.43 ng/ml, range= 1.34-4.39 ng/ml) with significant differences. It was also observed that patients on ARBs displayed the lowest concentration of D-dimer. This study showed that the use of antihypertensive drugs (ACE inhibitors or ARBs or Ca-channel blockers) prior to the infection with COVID-19 was not associated with the severity of disease and therefore, should not be discontinued during the course of infection.
References
AN, J., ZHOU, H., WEI, R., LUONG, T. Q., GOULD, M. K., MEFFORD, M. T., HARRISON, T. N., CREEKMUR, B., LEE, M.-S. & SIM, J. J. 2021. COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system. International Journal of Cardiology Hypertension, 100088. https://doi.org/10.1016/j.ijchy.2021.100088
BROJAKOWSKA, A., NARULA, J., SHIMONY, R. & BANDER, J. 2020. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC review topic of the week. Journal of the American College of Cardiology, 75, 3085-3095.
BUHL, K. B., OXLUND, C. S., FRIIS, U. G., SVENNINGSEN, P., BISTRUP, C., JACOBSEN, I. A. & JENSEN, B. L. 2014. Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro. Journal of Hypertension, 32, 1672-1677.
CHA, S. A., PARK, B. M. & KIM, S. H. 2018. Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor. The Korean Journal of Physiology & Pharmacology, 22, 447-456.
CHEN, Y., GUO, Y., PAN, Y. & ZHAO, Z. J. 2020. Structure analysis of the receptor binding of 2019-nCoV. Biochemical and Biophysical Research Communications, 525, 135-140.
DANSER, A. J., EPSTEIN, M. & BATLLE, D. 2020. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension, 75, 1382-1385.
FERRARIO, C. M., JESSUP, J., CHAPPELL, M. C., AVERILL, D. B., BROSNIHAN, K. B., TALLANT, E. A., DIZ, D. I. & GALLAGHER, P. E. 2005. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 111, 2605-2610.
GALÁN, M. & JIMÉNEZ-ALTAYÓ, F. 2020. Small resistance artery disease and ACE2 in hypertension: a new paradigm in the context of COVID-19. Frontiers in Cardiovascular Medicine, 7.
GUI, M., SONG, W., ZHOU, H., XU, J., CHEN, S., XIANG, Y. & WANG, X. 2017. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Research, 27, 119-129.
HOFFMANN, M., KLEINE-WEBER, H., SCHROEDER, S., KRÜGER, N., HERRLER, T., ERICHSEN, S., SCHIERGENS, T. S., HERRLER, G., WU, N.-H. & NITSCHE, A. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181, 271-280. e8.
HUNG, Y.-H., HSIEH, W.-Y., HSIEH, J.-S., LIU, C., TSAI, C.-H., LU, L.-C., HUANG, C.-Y., WU, C.-L. & LIN, C.-S. 2016. Alternative roles of STAT3 and MAPK signaling pathways in the MMPs activation and progression of lung injury induced by cigarette smoke exposure in ACE2 knockout mice. International Journal of Biological Sciences, 12, 454.
IGASE, M., KOHARA, K., NAGAI, T., MIKI, T. & FERRARIO, C. M. 2008. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertension Research, 31, 553-559.
KREUTZ, R., ALGHARABLY, E. A. E.-H., AZIZI, M., DOBROWOLSKI, P., GUZIK, T., JANUSZEWICZ, A., PERSU, A., PREJBISZ, A., RIEMER, T. G. & WANG, J.-G. 2020. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence. Cardiovascular Research, 116, 1688-1699.
KUBA, K., IMAI, Y., RAO, S., GAO, H., GUO, F., GUAN, B., HUAN, Y., YANG, P., ZHANG, Y. & DENG, W. 2005. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Medicine, 11, 875-879.
LI, F. 2016. Structure, function, and evolution of coronavirus spike proteins. Annual Review of Virology, 3, 237-261.
LIN, C.-I., TSAI, C.-H., SUN, Y.-L., HSIEH, W.-Y., LIN, Y.-C., CHEN, C.-Y. & LIN, C.-S. 2018. Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice. International Journal of Biological Sciences, 14, 253.
OCARANZA, M. P., RIQUELME, J. A., GARCÍA, L., JALIL, J. E., CHIONG, M., SANTOS, R. A. & LAVANDERO, S. 2020. Counter-regulatory renin–angiotensin system in cardiovascular disease. Nature Reviews Cardiology, 17, 116-129.
PATEL, V. B., ZHONG, J.-C., GRANT, M. B. & OUDIT, G. Y. 2016. Role of the ACE2/angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circulation Research, 118, 1313-1326.
SARDU, C., MAGGI, P., MESSINA, V., IULIANO, P., SARDU, A., IOVINELLA, V., PAOLISSO, G. & MARFELLA, R. 2020. Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy. Journal of the American Heart Association, 9, e016948.
SVENNINGSEN, P., HINRICHS, G. R., ZACHAR, R., YDEGAARD, R. & JENSEN, B. L. 2017. Physiology and pathophysiology of the plasminogen system in the kidney. Pflügers Archiv-European Journal of Physiology, 469, 1415-1423.
TURNER, A. J., HISCOX, J. A. & HOOPER, N. M. 2004. ACE2: from vasopeptidase to SARS virus receptor. Trends in Pharmacological Sciences, 25, 291-294.
WANG, H., LI, X., LI, T., ZHANG, S., WANG, L., WU, X. & LIU, J. 2020a. The genetic sequence, origin, and diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology & Infectious Diseases, 1-7.
WANG, Z., ZHANG, D., WANG, S., JIN, Y., HUAN, J., WU, Y., XIA, C., LI, Z., QI, X. & ZHANG, D. 2020b. A retrospective study from 2 centers in China on the effects of continued use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-
19. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 26, e926651-1.
ZHANG, H., PENNINGER, J. M., LI, Y., ZHONG, N. & SLUTSKY, A. S. 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46, 586-590.
ZHENG, H., LIU, X., SHARMA, N. M., LI, Y., PLIQUETT, R. U. & PATEL, K. P. 2016. Urinary proteolytic activation of renal epithelial Na+ channels in chronic heart failure. Hypertension, 67, 197-205.
